Tesamorelin and sermorelin are both growth hormone-releasing hormone analogs, but they are not interchangeable. They differ in regulatory status, approved indications, evidence base, formulation, and the clinical questions they are used to address.
| Feature | Tesamorelin | Sermorelin |
|---|---|---|
| Drug class | GHRH analog | GHRH analog |
| Current FDA-approved product | Yes, for a specific HIV-associated lipodystrophy indication | No current FDA-approved product |
| Weight-loss indication | No; the FDA-approved label states it is not for weight-loss management | No FDA-approved weight-loss indication |
| Clinical use | Diagnosis-specific | Requires careful discussion of regulatory status and evidence |
Tesamorelin is available as an FDA-approved prescription product for reducing excess abdominal fat in adults with HIV-associated lipodystrophy. The FDA-approved labeling specifically states that it is not for weight-loss management. That distinction matters when patients encounter broader body-composition claims online.
Sermorelin-containing products had historical FDA approvals for pediatric diagnostic or growth-related uses, but those products are no longer marketed as currently approved prescription products. Contemporary use should therefore be discussed with attention to current regulatory status, evidence, product quality, and appropriate medical oversight.
Explore: Tesamorelin Los Angeles, Sermorelin Therapy Los Angeles, CJC-1295 vs Sermorelin, and our Peptide Safety Guide.
No. Its FDA-approved indication is reduction of excess abdominal fat in adults with HIV-associated lipodystrophy, not general weight-loss management.
No. They are related GHRH analogs but are different molecules with different evidence and regulatory histories.
Written and medically reviewed by David Nazarian, MD, Board Certified in Internal Medicine. Educational information only.
